Disease progression of data-driven subtypes of Parkinson Disease (PD): 5-year longitudinal study from The Early Parkinson’s disease Longitudinal Singapore (PALS) cohort
Objective: To evaluate the non-motor symptom(NMS), motor and cognition progression among the Parkinson Disease (PD) clusters derived from data-driven approach. Background: Data-driven PD subtypes were…Disruption of Locus Coeruleus-Related Functional Networks in Parkinson’s Disease
Objective: We used resting-state functional MRI (rs-fMRI) to investigate the alterations of functional connectivity (FC) of LC-related resting-state networks (RSNs) and the associations between RSNs…Serum Zinc Deficiency could be associated with dementia conversion in Parkinson’s disease
Objective: To investigate the role of depletion or excess of various heavy metals on clinical characteristics of Parkinson's disease (PD) developing PD dementia in drug-naïve…Quantifying the value of multimodal MRI in outcomes prediction for STN DBS in PD
Objective: To compare the predictive value for motor outcomes of multimodal MRI to clinical predictors alone in STN DBS for PD. Background: STN DBS is…Investigating glutamate toxicity associated to Park2 mutations in pre-clinical models of Parkinson’s Disease
Objective: To generate and characterize induced pluripotent stem cells (iPSCs)-derived in vitro cellular models of Autosomal Recessive Juvenile Parkinsonism (ARJP) carrying Park2 mutations with a…Beyond Parkinson´s disease and synucleinopathies: unexpected identification of prodromal corticobasal syndrome by the updated MDS research criteria for prodromal PD
Objective: The aim of the current study was to determine the proportion of patients, initially classified as having prodromal Parkinson’s disease (pPD), phenoconverted to manifest…Referral patterns from primary care physicians to specialists among people with Parkinson’s disease or a Parkinson’s disease–related disorder
Objective: To evaluate referral patterns to a specialist by a primary care provider (PCP) or other healthcare provider (HCP) among people diagnosed with Parkinson’s disease…MDS-UPDRS III Off Severity Level changes as a marker of DBS response
Objective: To determine the change in MDS-UPDRS III severity level after Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) in patients with Parkinson’s disease (PD) and evaluate…Pharmacokinetics, Safety and Tolerability of Foslevodopa/Foscarbidopa Following Continuous Subcutaneous Infusion to Arm, Thigh and Flank compared to Abdomen in Parkinson’s Disease Patients
Objective: To characterize safety/tolerability and pharmacokinetics (PK) of levodopa (LD) and carbidopa (CD) after delivery of foslevodopa/foscarbidopa in Parkinson’s disease (PD) patients at 4 different…Sleep disorders in Parkinson’s disease patients. A case-control study.
Objective: To determine the quality of sleep, the type of sleep disorders and their correlations with motor impairment in Parkinson's disease (PD) patients. Background: Sleep…
- « Previous Page
- 1
- …
- 234
- 235
- 236
- 237
- 238
- …
- 436
- Next Page »